Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: methylphenidate hydrochloride Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Methylphenidate Treatment of Attention Deficits in Epilepsy

NCT02178995
View directory record Official record
Conditions
Epilepsy, Cognitive Deficits, Attention Deficits
Interventions
Methylphenidate
Drug
Lead sponsor
Kimford Jay Meador
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 25, 2026, 5:51 PM EDT
Not listed Phase 4 Interventional

Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

NCT03781765
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Atomoxetine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2024 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Results available

Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease

NCT00526630
View directory record Official record
Conditions
Parkinson's Disease, Gait Impairment
Interventions
Methylphenidate (MPD), Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
35 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 25, 2026, 5:51 PM EDT
Recruiting Phase 4 Interventional

Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD

NCT04781972
View directory record Official record
Conditions
ADHD - Combined Type
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

Effects of Methylphenidate on Cellular Abnormalities in Children With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00409708
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy, Behavior Therapy
Drug · Behavioral
Lead sponsor
Novartis
Industry
Eligibility
6 Years to 12 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2011 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Behavioral Effects of Drugs: Inpatient (35)

NCT03519022
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Cocaine, Placebo oral capsule, Methylphenidate
Drug
Lead sponsor
Craig Rush
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Sep 25, 2026, 5:51 PM EDT
Terminated Phase 4 Interventional Results available

Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children

NCT04987762
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Adhansia XR
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
4 Years to 12 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Little Rock, Arkansas • Colorado Springs, Colorado • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Sep 25, 2026, 5:51 PM EDT
Completed No phase listed Observational

IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents

NCT01232361
View directory record Official record
Conditions
ADHD, HIV
Interventions
Not listed
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Network
Eligibility
6 Years to 25 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
21
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Sep 25, 2026, 5:51 PM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Methylphenidate and Response to Alcohol Cues

NCT07306078
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Methylphenidate Pill, Placebo Pill
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Phase 4 Interventional

Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD

NCT00318981
View directory record Official record
Conditions
Adult ADHD
Interventions
Concerta
Drug
Lead sponsor
University of Maryland, College Park
Other
Eligibility
Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Brain Dopamine Function in Adults With ADHD

NCT00580814
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Experimental: methylphenidate treatment
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Results available

The Effects of ADHD Medication (TEAM) Study

NCT02293655
View directory record Official record
Conditions
ADHD
Interventions
OROS-Methylphenidate (MPH)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
7 Years to 11 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cannabidiol and CES1 Interactions in Healthy Subjects

NCT04603391
View directory record Official record
Conditions
Drug Interaction
Interventions
dl-Methylphenidate plus Cannabidiol, dl-Methylphenidate plus Cannabidiol Placebo solution
Drug
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 45 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2024 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Phase 3 Interventional

Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD

NCT02168127
View directory record Official record
Conditions
ADHD
Interventions
Drug: PRC-063, PRC-063
Drug
Lead sponsor
Rhodes Pharmaceuticals, L.P.
Industry
Eligibility
12 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
30
States / cities
Los Angeles, California • National City, California • Newport Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Phase 3 Interventional

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

NCT00151983
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
18
States / cities
Scottsdale, Arizona • San Marcos, California • Boulder, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

NCT01106430
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Lisdexamfetamine Dimesylate, Atomoxetine Hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Dothan, Alabama • Little Rock, Arkansas • Colton, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate

NCT00593112
View directory record Official record
Conditions
ADHD
Interventions
OROS methylphenidate, No intervention
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Not applicable Interventional Results available

Role of Apathy in the Effectiveness of Weight Loss Interventions

NCT00548652
View directory record Official record
Conditions
Obesity, Apathy
Interventions
MOVE, medical crisis councelling, methyphenidate
Behavioral · Drug
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
21 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation

NCT00794040
View directory record Official record
Conditions
Mood Disorder, Mental Disorder Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Add-on citalopram following optimized methylphenidate, Add-on placebo following optimized methylphenidate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Long-Duration Stimulant Treatment Study of ADHD in Young Children

NCT00257725
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
B-MPH
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
4 Years to 5 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Phase 3 Interventional

Ameliorating Attention Problems in Children With Sickle Cell Disease (SCD)

NCT01411280
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
methylphenidate
Drug
Lead sponsor
Temple University
Other
Eligibility
6 Years to 16 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Sep 25, 2026, 5:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study To Evaluate The Difference In iPad-Based Cognitive Video Game (Akili Interactive's Project: EVO) Performance In Amyloid-Positive Versus Amyloid-Negative Healthy Elderly Volunteers

NCT02265718
View directory record Official record
Conditions
Healthy
Interventions
Ritalin, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
70 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
4
States / cities
Long Beach, California • Hollywood, Florida • South Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

NCT00499863
View directory record Official record
Conditions
ADHD
Interventions
methylphenidate transdermal system, Placebo
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
13 Years to 17 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Scottsdale, Arizona • Lafayette, California • Wildomar, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 25, 2026, 5:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Methylphenidate for Ptsd and Stroke Veterans

NCT04885257
View directory record Official record
Conditions
PTSD, Stroke
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Sep 25, 2026, 5:51 PM EDT